Hcv protease inhibitors and uses thereof

A conjugate of the formula:

• Cys159-linker-inhibitor moiety,
• wherein:
• the Cys159 is Cys159 of HCV protease;
• the inhibitor moiety is a moiety that selectively binds HCV protease;
• the linker is a bivalent group resulting from the reaction of Cys159 of HCV protease with a L-Y warhead group, wherein
• L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two methylene units of L are independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, —C(O)O—, cyclopropylene, —O—, —N(R)—, or —C(O)—;
• Y is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 Re groups;
• and
• each Re is independently selected from -Q-Z, oxo, NO2, halogen, CN, a suitable leaving group selected from alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, acyl, diazonium, or C1-6 aliphatic substituted with oxo, halogen, NO2, or CN, wherein:
• Q is a bivalent C1-6 unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by —N(R)—, —S—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —SO—, or —SO2—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO2—, or —SO2N(R)—;
• and
• Z is hydrogen or C1-6 aliphatic substituted with oxo, halogen, NO2, or CN.

A conjugate of the formula:

• Cys159-linker-inhibitor moiety, wherein:
• the Cys159 is Cys159 of HCV protease;
• the inhibitor moiety is a moiety that selectively binds HCV protease;
• the linker is a bivalent group resulting from the reaction of Cys159 of HCV protease with a L-Y warhead group, wherein
• L-Y is selected from the group consisting of:

A conjugate of the formula:

• Cys16-linker-inhibitor moiety, wherein:
• the Cys16 is Cys16 of HCV protease;
• the inhibitor moiety is a moiety that selectively binds HCV protease;
• the linker is a bivalent group resulting from the reaction of Cys16 of HCV protease with a L-Y warhead group, wherein
• L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two methylene units of L are independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, —C(O)O—, cyclopropylene, —O—, —N(R)—, or —C(O)—;
• Y is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 Re groups;
• and
• each Re is independently selected from -Q-Z, oxo, NO2, halogen, CN, a suitable leaving group selected from alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, acyl, diazonium, or C1-6 aliphatic substituted with oxo, halogen, NO2, or CN, wherein:
• Q is a bivalent C1-6 unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by —N(R)—, —S—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —SO—, or —SO2—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO2—, or —SO2N(R)—;
• and
• Z is hydrogen or C1-6 aliphatic substituted with oxo, halogen, NO2, or CN.

A conjugate of the formula:

• Cys16-linker-inhibitor moiety, wherein:
• the Cys16 is Cys16 of HCV protease;
• the inhibitor moiety is a moiety that selectively binds HCV protease;
• the linker is a bivalent group resulting from the reaction of Cys16 of HCV protease with a L-Y warhead group, wherein
• L-Y is selected from the group consisting of: